German open label trial of riluzole 50 mg b.i.d. in treatment of amyotrophic lateral sclerosis (ALS)
Journal of the Neurological SciencesPublished 1 November 2000
D. Pongratz, B. Neundörfer, Wilhelm Fischer
Citations22
SJR quartileQ1
SJR score1.15
SNIP0.99
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Overall the safety profile found in the German centres was very similar to the profile seen in the total patient population and was more favourable than in the two published double-blind studies.
Abstract
The results of the study allow the conclusion that riluzole is well tolerated. The majority of adverse events were symptoms of the underlying disease and were not attributed to riluzole. Overall the safety profile found in the German centres was very similar to the profile seen in the total patient population and was more favourable than in the two published double-blind studies [New Engl J Med 330 (1994) 585; Lancet 347 (1996) 1425].
Keywords
ChemistryMedicine
The Annual Review of Pharmacology and ToxicologyExcitatory Amino Acid Transmitters
2,488 Citations1981J.C. Watkins, Richard H. Evans
New England Journal of MedicineA Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
2,157 Citations1994Gilbert Bensimon, Lucette Lacomblez +1 more
The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset, according to a prospective, double-blind, placebo-controlled trial in 155 outpatients with Amyotrophicateral sclerosis.
The LancetDose-ranging study of riluzole in amyotrophic lateral sclerosis
1,281 Citations1996Lucette Lacomblez, Gilbert Bensimon +4 more
A double-blind, placebo-controlled, multicentre study to confirm that riluzole is well tolerated and lengthens survival of patients with ALS, and suggests that the 100 mg dose of rILuzole has the best benefit-to-risk ratio.
New England Journal of MedicineDecreased Glutamate Transport by the Brain and Spinal Cord in Amyotrophic Lateral Sclerosis
1,174 Citations1992Jeffrey D. Rothstein, Lee J. Martin +1 more
ALS is associated with a defect in high-affinity glutamate transport that has disease, region, and chemical specificity and could lead to neurotoxic levels of extracellular glutamate and thus be pathogenic in ALS.
European Journal of PharmacologyThe neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1
256 Citations1993David Martin, Michael A. Thompson +1 more
It is demonstrated that 10-30 microM riluzole reduces the K(+)-evoked release of glutamate and aspartate from slices of hippocampal area CA1, and higher concentrations reduced gamma-aminobutyrate release.
European Journal of PharmacologyInhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes
210 Citations1993Marc-Williams Debono, Joëlle Le Guern +3 more
A direct but non-competitive action of riluzole on ionotropic glutamate receptors is suggested, similar to that of the channel blocker MK-801.
Neuropharmacology2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission—II Biochemical properties
206 Citations1985Jesús Bénavidès
The results are compatible with a possible antagonism by PK 26124 of the excitatory amino acid neurotransmission and may explain its anticonvulsant properties.
Neuropharmacology2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission—I
195 Citations1985J Mizoule, Brian S. Meldrum +7 more
Data suggest that PK 26124 possesses antagonistic properties of excitatory dicarboxylic amino acids, which may contribute to its anticonvulsant action.
PubMedExcitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis.
177 Citations1995Rothstein Jd
Experimental paradigms suggest that, even if secondary, glutamate could contribute to the death of motor neurons, and interventions to minimize the toxicity of glutamate (e.g., receptor antagonists, release inhibitors, or antioxidants) could partially ameliorate the degeneration of motor neuron.
British Journal of PharmacologyAntagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action
129 Citations1994Jean‐Pierre Hubert, Jean-Christophe Delumeau +3 more
It is concluded that riluzole has a dual action on cerebellar granule cells, both blocking voltage‐dependent sodium channels and interfering with NMDA receptor‐mediated responses via a pertussis toxin‐sensitive mechanism.
Brain Research ReviewsAmino acids as dietary excitotoxins: A contribution to understanding neurodegenerative disorders
117 Citations1993Brian S. Meldrum
The possibility that some acidic amino acids occurring naturally or as additives in the diet can act as excitotoxins producing central nervous system pathology has been the subject of extensive debate in the last 20 years and is reviewed.
Journal of the Neurological SciencesExcitotoxicity and motor neurone disease: A review of the evidence
94 Citations1994Pamela J. Shaw
The evidence, while still circumstantial, is sufficient to warrant further research effort in this field, not least because the emergence of pharmacological agents which modify specific aspects of excitatory amino acid neurotransmission offer the possibility of therapeutic intervention in MND.
Neuroscience LettersPertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on d[3H]aspartate release from cultured cerebellar granule cells
79 Citations1992Adam Doble, Jean‐Pierre Hubert +1 more
Neuroscience LettersNeuroprotective effects of riluzole on or veratridine-induced neurotoxicity in rat hippocampal slices
70 Citations1994C. Malgouris, Marc Daniel +1 more
The view that the neuroprotective properties of riluzole could be exerted via two distinct mechanisms of action is supported.
NeuroreportNeuroprotective effects of riluzole in ALS CSF toxicity
67 Citations1994Philippe Couratier, Philippe Sindou +3 more
Riluzole (5 x 10(-7) M) which reduces excitatory amino acid release, could represent a new pharmacological agent susceptible to be proposed to patients affected by this dramatic neurological disease.
NeurologyGlutamate dehydrogenase and aspartate aminotransferase in leukocytes of patients with motor neuron disease
45 Citations1989Jacques Hugon, F Tabaraud +3 more
Abnormal cellular glutamate metabolism might be involved in the pathogenesis of motor neuron disease and in affected and nonaffected subjects.